A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC
Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic monoclonal antibodies (mAbs) now play an important role in cancer therapy, effective targeted mAbs are...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2282250 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035470110556160 |
|---|---|
| author | Huiting Wu Chang Liu Qiang Yuan Yan Qiao Yongwei Ding Lina Duan Wenjing Li Mengjia Zhang Xuhua Zhang Yanan Jiang Jing Lu Ziming Dong Tao Wang Kangdong Liu Jimin Zhao |
| author_facet | Huiting Wu Chang Liu Qiang Yuan Yan Qiao Yongwei Ding Lina Duan Wenjing Li Mengjia Zhang Xuhua Zhang Yanan Jiang Jing Lu Ziming Dong Tao Wang Kangdong Liu Jimin Zhao |
| author_sort | Huiting Wu |
| collection | DOAJ |
| description | Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic monoclonal antibodies (mAbs) now play an important role in cancer therapy, effective targeted mAbs are still lacking for ESCC. B7-H3 is highly expressed in a variety of tumors and has emerged as a promising therapeutic target. Several mAbs against B7-H3 have advanced to clinical trials, but their development has not yet been pursued for ESCC. Here, we developed a humanized and Fc-engineered anti-B7H3 mAb 24F-Hu-mut2 and systematically evaluated its anti-tumor activity in vitro and in vivo. The 24F-Hu-mut2 was humanized and modified in Fc fragment to obtain stronger antibody-dependent cell-mediated cytotoxicity(ADCC) activity and nanomolar affinity. Furthermore, both of ESCC cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mice models indicated that 24F-Hu-mut2 displayed potent in vivo anti-tumor activity. In addition, a computational docking model showed that the mAb bound to IgC1 and IgC2 domain of B7-H3, which is closer to the cell membrane. Consistently, our ELISA results verified the binding of 24F-Hu-WT and IgC1 and IgC2. Our results indicate that 24F-Hu-mut2 has significant anti-ESCC activity both in vitro and in vivo, and this monoclonal antibody may be a promising antibody against ESCC and other B7-H3 overexpressing tumors. |
| format | Article |
| id | doaj-art-11944828d30a4dccb33759dac6e0f864 |
| institution | DOAJ |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-11944828d30a4dccb33759dac6e0f8642025-08-20T02:57:29ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2282250A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCCHuiting Wu0Chang Liu1Qiang Yuan2Yan Qiao3Yongwei Ding4Lina Duan5Wenjing Li6Mengjia Zhang7Xuhua Zhang8Yanan Jiang9Jing Lu10Ziming Dong11Tao Wang12Kangdong Liu13Jimin Zhao14Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, Shaoxing People Hospital, Shaoxing, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaThe Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaTelethon Kids Institute, University of Western Australia, Perth, AustraliaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, ChinaEsophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic monoclonal antibodies (mAbs) now play an important role in cancer therapy, effective targeted mAbs are still lacking for ESCC. B7-H3 is highly expressed in a variety of tumors and has emerged as a promising therapeutic target. Several mAbs against B7-H3 have advanced to clinical trials, but their development has not yet been pursued for ESCC. Here, we developed a humanized and Fc-engineered anti-B7H3 mAb 24F-Hu-mut2 and systematically evaluated its anti-tumor activity in vitro and in vivo. The 24F-Hu-mut2 was humanized and modified in Fc fragment to obtain stronger antibody-dependent cell-mediated cytotoxicity(ADCC) activity and nanomolar affinity. Furthermore, both of ESCC cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mice models indicated that 24F-Hu-mut2 displayed potent in vivo anti-tumor activity. In addition, a computational docking model showed that the mAb bound to IgC1 and IgC2 domain of B7-H3, which is closer to the cell membrane. Consistently, our ELISA results verified the binding of 24F-Hu-WT and IgC1 and IgC2. Our results indicate that 24F-Hu-mut2 has significant anti-ESCC activity both in vitro and in vivo, and this monoclonal antibody may be a promising antibody against ESCC and other B7-H3 overexpressing tumors.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2282250ADCCB7-H3Esophageal squamous cell carcinomaFc engineeringmonoclonal antibody |
| spellingShingle | Huiting Wu Chang Liu Qiang Yuan Yan Qiao Yongwei Ding Lina Duan Wenjing Li Mengjia Zhang Xuhua Zhang Yanan Jiang Jing Lu Ziming Dong Tao Wang Kangdong Liu Jimin Zhao A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC OncoImmunology ADCC B7-H3 Esophageal squamous cell carcinoma Fc engineering monoclonal antibody |
| title | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC |
| title_full | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC |
| title_fullStr | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC |
| title_full_unstemmed | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC |
| title_short | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC |
| title_sort | novel fc enhanced humanized monoclonal antibody targeting b7 h3 suppresses the growth of escc |
| topic | ADCC B7-H3 Esophageal squamous cell carcinoma Fc engineering monoclonal antibody |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2282250 |
| work_keys_str_mv | AT huitingwu anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT changliu anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT qiangyuan anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yanqiao anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yongweiding anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT linaduan anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT wenjingli anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT mengjiazhang anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT xuhuazhang anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yananjiang anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT jinglu anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT zimingdong anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT taowang anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT kangdongliu anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT jiminzhao anovelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT huitingwu novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT changliu novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT qiangyuan novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yanqiao novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yongweiding novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT linaduan novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT wenjingli novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT mengjiazhang novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT xuhuazhang novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT yananjiang novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT jinglu novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT zimingdong novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT taowang novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT kangdongliu novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc AT jiminzhao novelfcenhancedhumanizedmonoclonalantibodytargetingb7h3suppressesthegrowthofescc |